KD 3010 / Kalypsys - LARVOL DELTA

Neonatal sevoflurane exposure disrupted fatty acids metabolism, leading to hypomyelination and neurological impairments. (PubMed, Biomed Pharmacother) - "Furthermore, the PPARβ agonist KD3010 attenuated the adverse effects of sevoflurane exposure on cognitive function and myelination. Sevoflurane-induced myelin impairment is associated with changes in fatty acid content and composition, which may be mediated by the PPARβ pathway. These findings highlight the pivotal role of long-chain fatty acids in neonatal sevoflurane-associated neurotoxicity and open a new window for developing therapeutic strategies for sevoflurane-associated neurodevelopmental impairments."

Journal • Alzheimer's Disease • Anesthesia • Cognitive Disorders • Metabolic Disorders

Erucic acid, a nutritional PPARδ-ligand may influence Huntington's disease pathogenesis. (PubMed, Metab Brain Dis) - "PPARδ directly involves in the pathogenesis of HD and treatment with a brain-permeable PPARδ-agonist (KD3010) alleviates its severity in mice...Moreover, erucamide, an endogenous EA-amide derivative regulating angiogenesis and water balance, exerts antidepressive and anxiolytic effects in mice. Hitherto, no study has investigated the therapeutic potential of EA in HD and we believe that it strongly merits to be studied in animal models of HD as a potential therapeutic."

Journal • Review